by The Novartis offices in Basel, Switzerland. Keystone / Georgios Kefalas Swiss pharma company Novartis will pay 9 million (CHF688 million) to US authorities in an out-of-court settlement over various charges, including that the company bribed doctors to use its drugs. Audrey Strauss, the acting Manhattan US Attorney, said the firm had paid out for “speaking fees, exorbitant meals, and top-shelf alcohol that were nothing more than bribes to get doctors across the country to prescribe Novartis’s drugs.” Essentially, Novartis admitted to having organised thousands of lavish conferences and events ostensibly aimed at “further education”. Guest speakers were paid large amounts to attend. In return, the doctors were incentivised to prescribe Novartis products, such as
Topics:
Swissinfo considers the following as important: 3) Swiss Markets and News, 3.) Swiss Info, Audrey Strauss, Featured, Law and order, newsletter, Novartis, William F Sweeney Jr
This could be interesting, too:
Robert P. Murphy writes Simon Guenzl vs. Dave Smith on Open Borders
Sean Twomey writes Why Politicians and Bureaucrats Choose Politics over Sound Economics
David Gordon writes The Non-Austrian Theory of the Nonbusiness Cycle
Marc Chandler writes Where We Stand
The Novartis offices in Basel, Switzerland. Keystone / Georgios Kefalas
Swiss pharma company Novartis will pay $729 million (CHF688 million) to US authorities in an out-of-court settlement over various charges, including that the company bribed doctors to use its drugs.
Audrey Strauss, the acting Manhattan US Attorney, said the firm had paid out for “speaking fees, exorbitant meals, and top-shelf alcohol that were nothing more than bribes to get doctors across the country to prescribe Novartis’s drugs.”
Essentially, Novartis admitted to having organised thousands of lavish conferences and events ostensibly aimed at “further education”. Guest speakers were paid large amounts to attend.
In return, the doctors were incentivised to prescribe Novartis products, such as drugs for high blood pressure and diabetes, which were then reimbursed by state health authorities.
“Not only did Novartis incentivise doctors to host these speaking events, reps bribed the doctors to write more prescriptions of the company’s drugs to give Novartis an advantage over competitors within their field,” said William F Sweeney Jr, head of New York’s FBI office.
“Greed replaced the responsibility the public expects from those who practice medicine.”
As part of the agreement with US authorities, Novartis has signed a five-year code of good conduct. The Basel-based firm also said on Thursday that it was revising its methods of providing medical training, notably by planning more online webinars.
In a statement, Novartis CEO Vas Narasimhan said that the company had already changed (the charges in question were raised by a whistle-blower in 2011) and that it had “new leadership, a stronger culture, and a more comprehensive commitment to ethics”.
“With these agreements we mark an important milestone on our journey to build trust with society as we continue re-imagining medicine to improve and extend lives all around the world,” Narasimhan said.
A week ago Novartis and two of its subsidiaries admitted to further bribery schemes involving dealings in Vietnam and Greece, and agreed to pay some $347 million to settle US investigations.
As of Thursday, the stock market has not reacted particularly strongly: the Novartis share price dropped 0.8%, around the same as its competitor Roche.
You Might Also Like
Glencore faces Swiss probe over alleged Congo corruption
The Office of the Attorney General of Switzerland (OAG) has opened a criminal probe into Swiss-based commodity trader and miner Glencore over alleged corruption in the Democratic Republic of the Congo, where it mines copper and cobalt.
Swiss oil traders and banks burned by Venezuela ties
Several Swiss companies and banks have found themselves in the line of fire as the United States ramps up pressure on the Venezuelan government. Washington has sanctioned numerous top officials for money laundering and drug trafficking in the oil-rich but economically flailing Latin American nation.
Swiss customs uncover blackmarket animal drugs scam
More than 200 farmers, many in Switzerland, are suspected of buying illegal medicaments for their livestock from a French blackmarket dealer. Swiss customs uncovered the scam when the veterinarian was stopped at the border with his car full of animal drugs.
Swiss public transport expected to lose CHF1.5 billion due to Covid-19
The collapse in the number of commuters and other passengers on Swiss trains and buses due to the pandemic is likely to leave a big hole in the finances of public transport companies. The Le Matin Dimanche and SonntagsZeitung newspapers reported on Sunday that Alliance SwissPass, the national public transport organisation, expects the number of yearly national train passes to fall by 6% and half-price annual passes to drop by 1% by the end of the year.
A Swiss-Japanese alliance that has thrived in the crisis
It was the start of one of the most unusual cross-cultural marriages when Roche bought a controlling stake in Chugai Pharmaceutical for $1.4bn back in 2002, promising arm’s length management. In the course of the 18 months of negotiations it took to reach a deal, Chugai, a Japanese pioneer in biotechnology, presented a single sheet of paper with a list of conditions it would not budge on, the main ones being management autonomy and the continued listing of its shares in Tokyo.
Audit office denies ‘mass phenomenon’ of Covid-19 credit abuse
An interim report on government pay-outs to businesses during the Covid-19 crisis has revealed that there is suspected abuse in less than 1% of cases. Тhe Federal Audit Office investigated some 94,000 coronavirus loans amounting to CHF11.4 billion ($12 billion). It found indications of abuse in about 400 cases, which amounts to about CHF88 million in guarantees.
Hands-off regulation of sustainable finance draws mixed response
Extra rules will only be imposed on the sustainable finance sector if banks fail to properly police themselves, says the Swiss government. The hands-off regulatory approach to ethical investing has been welcomed by financial players, but criticised by NGOs. Unveiling a report on sustainable finance on Friday, Finance Minister Ueli Maurer said legislators would stay in the background as a last resort measure.
Fewer cows, more cars: Switzerland misses its emission targets
Switzerland’s emissions have declined over the last 30 years, but not enough to meet the national targets set for 2020. What’s behind the gap? By 2020, greenhouse gas emissions in Switzerland should be down by 20% from what they were in 1990. That’s the target outlined in the federal CO2 law.
Tags: Audrey Strauss,Featured,Law and order,newsletter,Novartis,William F Sweeney Jr